Search Results - "Aleissa, Muneerah M"

New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19 by Aleissa, Muneerah M, Silverman, Emily A, Paredes Acosta, Luisa M, Nutt, Cameron T, Richterman, Aaron, Marty, Francisco M

“…Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with coronavirus disease 2019 (COVID-19)…”
Get full text

Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage by Alsuhebany, Nada, Alshehri, Bashayer, Aldairem, Atheer, Aleissa, Muneerah M., AlQahtani, Hajar, Albarqi, Khalid, Almotairi, Basil, AlAmri, Mohammed, Alanazi, Walid, Alay, Saeed, Alahmari, Bader, Alzahrani, Mohsen

Get full text

Peri-operative opioid and sedation requirements in patients who use marijuana and are undergoing total knee or total hip arthroplasty: A retrospective study by Aleissa, Muneerah M., Ahern, Krystina L., Stern, Gretchen M.

“…•Patients using marijuana had increased opioid usage 72 h after THA/TKA surgery•Patients using marijuana had higher pain scores within 72 h of THA/TKA…”
Get full text

Echinocandin exposures in obese patients: A scoping review and clinical perspectives by Alsowaida, Yazed S, Alamer, Ahmad, Thabit, Abrar K, Almulhim, Abdulaziz S, Aleissa, Muneerah M, Kalbasi, Alireza, Eljaaly, Khaled, Almangour, Thamer A, Erstad, Brian L

“…Abstract Purpose Echinocandins are favored drugs for the treatment of fungal infections. There is growing evidence that obese patients treated with…”
Get full text

Triazole antifungal use for prophylaxis and treatment of invasive fungal diseases for patients receiving gilteritinib by Aleissa, Muneerah M., Alshehri, Bashayer S., Gonzalez-Bocco, Isabel H., McDonnell, Anne M., Leblebjian, Houry, Marty, Francisco M., Luskin, Marlise R.

“…•Concomitant gilteritinib and triazole administration was not associated with an increase in gilteritinib-related adverse events.•Severity of…”
Get full text

Low incidence of invasive fungal disease following CD19 chimeric antigen receptor T-cell therapy for non-Hodgkin lymphoma by Little, Jessica S., Aleissa, Muneerah M., Beluch, Katherine, Gonzalez-Bocco, Isabel H., Marty, Francisco M., Manne-Goehler, Jennifer, Koo, Sophia, Hammond, Sarah P., Jacobson, Caron A.

“…CAR T-cell therapy has revolutionized the treatment of hematologic malignancies, although its use may be complicated by toxicities, including cytokine release…”
Get full text

Implementation of a Pharmacist-Driven Vancomycin Area Under the Concentration-Time Curve Monitoring Program Using Bayesian Modeling in Outpatient Parenteral Antimicrobial Therapy by Gillett, Eric, Aleissa, Muneerah M, Pearson, Jeffrey C, Solomon, Daniel A, Kubiak, David W, Dionne, Brandon, Edrees, Heba H, Okenla, Adetoun, Chan, Brian T

“…Abstract Background Current vancomycin monitoring guidelines recommend monitoring 24-hour area under the concentration-time curve (AUC) to minimum inhibitory…”
Get full text

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Immunogenicity among Chimeric Antigen Receptor T Cell Therapy Recipients by Aleissa, Muneerah M., Little, Jessica S., Davey, Sonya, Saucier, Anna, Zhou, Guohai, Gonzalez-Bocco, Isabel H., Crombie, Jennifer L., Looka, Andrew, Baden, Lindsey R., Issa, Nicolas C., Hammond, Sarah P., Jacobson, Caron A., Sherman, Amy C.

“…•The seropositivity rate to severe acute respiratory syndrome coronavirus 2 vaccinations was 64% in recipients of chimeric antigen receptor T cell…”
Get full text

Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft by Little, Jessica S., Duléry, Rémy, Shapiro, Roman M., Aleissa, Muneerah M., Prockop, Susan E., Koreth, John, Ritz, Jerome, Antin, Joseph H., Cutler, Corey, Nikiforow, Sarah, Romee, Rizwan, Issa, Nicolas C., Ho, Vincent T., Baden, Lindsey R., Soiffer, Robert J., Gooptu, Mahasweta

“…•Opportunistic infections (CMV, AdV, EBV, and IFD) were assessed in 354 patients undergoing HCT with PTCy-based GVHD prophylaxis within 1 year.•Haploidentical…”
Get full text

Clarithromycin–Rifampin-Based Treatment for Nontuberculous Mycobacteria Infections in Immunocompromised Patients who Require Concomitant CYP-Metabolized Medications by Gonzalez-Bocco, Isabel H, Aleissa, Muneerah M, Zhou, Eric, Manne-Goehler, Jennifer, Koo, Sophia, Cheng, Matthew P, Marty, Francisco M

“…Abstract Clarithromycin (CYP inhibitor) can be used instead of azithromycin for nontuberculous mycobacteria therapy in patients requiring CYP substrates to…”
Get full text

Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome by Little, Jessica S., Shapiro, Roman M., Aleissa, Muneerah M., Kim, Austin, Chang, Jun Bai Park, Kubiak, David W., Zhou, Guohai, Antin, Joseph H., Koreth, John, Nikiforow, Sarah, Cutler, Corey S., Romee, Rizwan, Issa, Nicolas C., Ho, Vincent T., Gooptu, Mahasweta, Soiffer, Robert J., Baden, Lindsey R.

“…•The rise of antifungal resistance represents a major threat for patients undergoing hematopoietic cell transplantation (HCT).•Improved understanding of…”
Get full text

The Relationship Between Antibiotic Agent and Mortality in Patients With Febrile Neutropenia due to Staphylococcal Bloodstream Infection: A Multicenter Cohort Study by Aleissa, Muneerah M, Gonzalez-Bocco, Isabel H, Zekery-Saad, Sara, Kubiak, David W, Zhang, Eric M, Signorelli, Jessie, Hammond, Sarah P, Mohareb, Amir M, Luskin, Marlise R, Manne-Goehler, Jennifer, Marty, Francisco M

“…Abstract Background Methicillin-susceptible Staphylococcus aureus (MSSA) is a common cause of bloodstream infection (BSI) in patients with febrile neutropenia,…”
Get full text

2097. Bacterial Infections in the Setting of Late Neutropenia Following CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Non-Hodgkin Lymphoma (NHL) by Little, Jessica S, Hammond, Sarah P, Jacobson, Caron, Aleissa, Muneerah M

“…Abstract Background Cellular therapies such as CAR-T therapy have excellent clinical efficacy for treatment of relapsed and refractory hematologic…”
Get full text

329. Vancomycin area under the concentration-time curve monitoring from Bayesian modeling in outpatient parenteral antimicrobial therapy by Gillett, Eric M, Aleissa, Muneerah M, Pearson, Jeffrey C, Kubiak, David W, Dionne, Brandon, Chan, Brian T

“…Abstract Background Current vancomycin monitoring guidelines recommend area under the concentration-time curve to minimum inhibitory concentration (AUC/MIC)…”
Get full text

1399. Clarithromycin–Rifampin-based Treatment for Non-tuberculous Mycobacterial Infections in Immunocompromised Patients Who Require Concomitant CYP-Metabolized Medications by Gonzalez-Bocco, Isabel H, Aleissa, Muneerah M, Cheng, Matthew, Manne-Goehler, Jennifer, Marty, Francisco M

“…Abstract Background Non-tuberculous mycobacteria (NTM) are causes of pulmonary and extrapulmonary disease that frequently affect immunocompromised hosts (ICH)…”
Get full text

2334. The effectiveness of bivalent COVID-19 booster among patients with hematologic malignancies by Aleissa, Muneerah M, Davey, Sonya, Rooks, Rebecca, Izaguirre, Natalie E, Yates, Bridget, Kanwal, Urwah, Baden, Lindsey R, Issa, Nicolas C, Sherman, Amy C

“…Abstract Background Patients with hematologic malignancies remain at higher risk for developing severe SARS-CoV-2 infections and have reduced immune responses…”
Get full text

1073. SARS-CoV-2 Vaccine-Induced Immunogenicity among Hematopoietic Stem Cell Transplant Recipients (HSCT) by Kokogho, Afoke, Aleissa, Muneerah M, Chang, Jun Bai Park, Walsh, Stephen R, Crowell, Trevor A, Baden, Lindsey R, Sherman, Amy C

“…Abstract Background SARS-CoV-2 vaccination reduces the risk and severity of coronavirus disease 2019 (COVID-19), but immunogenicity may be reduced in patients…”
Get full text

1939. COVID-19 vaccine immunogenicity among CD19 receptor T-cell (CAR-T) therapy by Aleissa, Muneerah M, Little, Jessica S, Davey, Sonya, Gonzalez-Bocco, Isabel H, Looka, Andrew, Issa, Nicolas C, Hammond, Sarah P, Jacobson, Caron, Sherman, Amy C

“…Abstract Background Patients receiving CAR-T therapy may have impaired humoral responses to SARS-CoV-2 vaccinations due to their high net state of…”
Get full text

186. Evaluating Clinical Outcomes for Treatment of Staphylococcal Bloodstream Infection in Patients with Febrile Neutropenia by Aleissa, Muneerah M, Gonzalez-Bocco, Isabel H, Kubiak, David W, Zekery-Saad, Sara, Signorelli, Jessie, Hammond, Sarah P, Manne-Goehler, Jennifer, Marty, Francisco M

“…Abstract Background Staphylococcus aureus bloodstream infections (BSIs) in patients with febrile neutropenia (FN) is associated with a mortality rate of up to…”
Get full text

733. Letermovir treatment for refractory or resistant cytomegalovirus infection or disease with concurrent organ dysfunction: an interim analysis of a Phase 2 open label study by Gonzalez-Bocco, Isabel H, Cheng, Matthew, Aleissa, Muneerah M, Arbona, Esther I, Chen, Kaiwen, Zhou, Eric, Beluch, Katherine, Cho, Alyssa, Burchett, Sandra, Hammond, Sarah P, Issa, Nicolas C, Sherman, Amy C, Marty, Francisco M

“…Abstract Background Cytomegalovirus (CMV) disease is associated with increased morbidity and mortality following solid organ and hematopoietic cell…”
Get full text